RBC Capital analyst Luca Issi maintained a Buy rating on uniQure (QURE – Research Report) on January 3 and set a price target of $28.00. The company’s shares closed yesterday at $6.56.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Crispr Therapeutics AG, and BioMarin Pharmaceutical. According to TipRanks, Issi has an average return of -19.5% and a 30.30% success rate on recommended stocks.
In addition to RBC Capital, uniQure also received a Buy from William Blair’s Sami Corwin in a report issued on December 19. However, on the same day, Mizuho Securities maintained a Hold rating on uniQure (NASDAQ: QURE).
See Insiders’ Hot Stocks on TipRanks >>
Based on uniQure’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.41 million and a GAAP net loss of $89.57 million. In comparison, last year the company earned a revenue of $1.45 million and had a GAAP net loss of $47.86 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure (QURE) Company Description:
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- Here are the Top 10 Female Analysts of 2023, According to TipRanks
- uniQure announces update on Phase I/II trials of AMT-130 gene therapy
- uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- uniQure downgraded to Neutral from Buy at Mizuho
- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
